glp-1 type 2 diabetes receptor agonists in the treatment of e MCT2D | The Benefits of

doi: 10.1101/2024.12.16.24317793.Google Scholar Kenny, LC, Brown, LW, Ortea, P et al

In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) launched a review in July 2023 into the risk of suicidal thoughts and thoughts of self-harm associated with GLP-1 RAs, including exenatide, liraglutide, lixisenatide, dulaglutide and semaglutide

TL;DR GLP-1 drugs such as semaglutide, tirzepatide, and liraglutide can help reduce appetite and body weight, but emerging research shows they may also increase the risk of protein, vitamin, and mineral deficiencies, especially when appetite drops sharply and food intake becomes too low or too limited

Vella V, Malaguarnera R, Nicolosi ML, Morrione A, Belfiore A